GSK to buy Sierra Oncology for $1.9bn

GlaxoSmithKline (GSK) has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Generics

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

13 December 2021 Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.

More on this story

Big Pharma

GSK targets Pfizer over newly approved RSV vaccine

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Generics

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

More on this story

Big Pharma

GSK targets Pfizer over newly approved RSV vaccine

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Generics

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation